297 related articles for article (PubMed ID: 26075238)
21. Developing clinical trials for biosimilars.
Bui LA; Taylor C
Semin Oncol; 2014 Feb; 41 Suppl 1():S15-25. PubMed ID: 24560024
[TBL] [Abstract][Full Text] [Related]
22. Biosimilars lining up to compete with Herceptin--opportunity knocks.
Nelson KM; Gallagher PC
Expert Opin Ther Pat; 2014 Nov; 24(11):1149-53. PubMed ID: 25307085
[TBL] [Abstract][Full Text] [Related]
23. Improving the power to establish clinical similarity in a Phase 3 efficacy trial by incorporating prior evidence of analytical and pharmacokinetic similarity.
Zeng D; Pan J; Hu K; Chi E; Lin DY
J Biopharm Stat; 2018; 28(2):320-332. PubMed ID: 29173074
[TBL] [Abstract][Full Text] [Related]
24. Challenges of developing and validating immunogenicity assays to support comparability studies for biosimilar drug development.
Cai XY; Thomas J; Cullen C; Gouty D
Bioanalysis; 2012 Sep; 4(17):2169-77. PubMed ID: 23013399
[TBL] [Abstract][Full Text] [Related]
25. Scientific and statistical considerations in evaluating the analytical similarity of ABP 501 to adalimumab.
Sivendran R; Ramírez J; Ramchandani M; Liu J
Immunotherapy; 2018 Aug; 10(11):1011-1021. PubMed ID: 30071739
[TBL] [Abstract][Full Text] [Related]
26. Target-directed development and preclinical characterization of the proposed biosimilar rituximab GP2013.
da Silva A; Kronthaler U; Koppenburg V; Fink M; Meyer I; Papandrikopoulou A; Hofmann M; Stangler T; Visser J
Leuk Lymphoma; 2014 Jul; 55(7):1609-17. PubMed ID: 24024472
[TBL] [Abstract][Full Text] [Related]
27. Biosimilar medicines - Review.
Dos Reis C; Teixo R; Mendes F; Cruz RS
Int J Risk Saf Med; 2016 Mar; 28(1):45-60. PubMed ID: 27176756
[TBL] [Abstract][Full Text] [Related]
28. Assessment of structural and functional similarity of biosimilar products: Rituximab as a case study.
Nupur N; Chhabra N; Dash R; Rathore AS
MAbs; 2018 Jan; 10(1):143-158. PubMed ID: 29200314
[TBL] [Abstract][Full Text] [Related]
29. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.
Braun J; Kudrin A
Immunotherapy; 2015; 7(2):73-87. PubMed ID: 25713985
[TBL] [Abstract][Full Text] [Related]
30. Assessing analytical comparability of biosimilars: GCSF as a case study.
Nupur N; Singh SK; Narula G; Rathore AS
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Oct; 1032():165-171. PubMed ID: 27289250
[TBL] [Abstract][Full Text] [Related]
31. Biosimilar monoclonal antibodies: preclinical and clinical development aspects.
Gonçalves J; Araújo F; Cutolo M; Fonseca JE
Clin Exp Rheumatol; 2016; 34(4):698-705. PubMed ID: 27383278
[TBL] [Abstract][Full Text] [Related]
32. Recommendations for the Development and Validation of Immunogenicity Assays in Support of Biosimilar Programs.
Civoli F; Kasinath A; Cai XY; Wadhwa M; Exley A; Oldfield P; Alvandkouhi S; Schaffar G; Chappell J; Bowsher R; Devanarayan V; Marini J; Rebarchak S; Anderson M; Koppenburg V; Lester T
AAPS J; 2019 Dec; 22(1):7. PubMed ID: 31792633
[TBL] [Abstract][Full Text] [Related]
33. Analytical similarity assessment of rituximab biosimilar CT-P10 to reference medicinal product.
Lee KH; Lee J; Bae JS; Kim YJ; Kang HA; Kim SH; Lee SJ; Lim KJ; Lee JW; Jung SK; Chang SJ
MAbs; 2018 Apr; 10(3):380-396. PubMed ID: 29469653
[TBL] [Abstract][Full Text] [Related]
34. Considerations in the early development of biosimilar products.
Li EC; Abbas R; Jacobs IA; Yin D
Drug Discov Today; 2015 May; 20 Suppl 2():1-9. PubMed ID: 25572407
[TBL] [Abstract][Full Text] [Related]
35. Milestones over the development of SB3, a trastuzumab biosimilar.
Pivot X; Bondarenko I; Petit T; Curtit E
Future Oncol; 2018 Nov; 14(27):2795-2803. PubMed ID: 29927335
[TBL] [Abstract][Full Text] [Related]
36. Challenges in the implementation of trastuzumab biosimilars: an expert panel's recommendations.
Pivot X; Aulagner G; Blay JY; Fumoleau P; Kaliski A; Sarkozy F; Limat S
Anticancer Drugs; 2015 Nov; 26(10):1009-16. PubMed ID: 26352219
[TBL] [Abstract][Full Text] [Related]
37. Trastuzumab biosimilar in metastatic breast cancer: Evaluating equivalence with originator using network meta-analysis
.
Mengato D; Chiumente M; Messori A
Int J Clin Pharmacol Ther; 2019 Mar; 57(3):160-162. PubMed ID: 30574866
[TBL] [Abstract][Full Text] [Related]
38. Clinical development and trial design of biosimilar products: a Japanese perspective.
Nagasaki M; Ando Y
J Biopharm Stat; 2014; 24(6):1165-72. PubMed ID: 25033370
[TBL] [Abstract][Full Text] [Related]
39. New Alternatives for Autoimmune Disease Treatments: Physicochemical and Clinical Comparability of Biosimilar Etanercept.
Miranda-Hernández MP; López-Morales CA; Perdomo-Abúndez FC; Salazar-Flores RD; Ramírez-Ibanez ND; Pérez NO; Molina-Pérez A; Revilla-Beltri J; Flores-Ortiz LF; Medina-Rivero E
J Immunol Res; 2016; 2016():9697080. PubMed ID: 27382576
[TBL] [Abstract][Full Text] [Related]
40. Randomised clinical endpoint studies for trastuzumab biosimilars: a systematic review.
Coory M; Thornton K
Breast Cancer Res Treat; 2019 Jul; 176(1):17-25. PubMed ID: 30980209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
